ReviewCurrent opinion in microbiology2010
The future of the β-lactams.
Review in Current opinion in microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- Zinc starvation uncovers bacterial host-specific proteases that shape NDM adaptability inmBio · 2026Article
- Diazacyclobutene Ring Cleavage Provides 1,2-Diazetidin-3-ones via Intramolecular Nucleophilic Cyclization.Organic letters · 2025Article
- OXA β-lactamases frommBio · 2025Article
- OXA β-lactamases frombioRxiv : the preprint server for biology · 2024Article
- Article
- Targeting bacterial degradation machinery as an antibacterial strategy.The Biochemical journal · 2023Review
- Contra-thermodynamic halolactonization of lactam-tethered 5-aryl-4(RSC advances · 2022Article
- Stereocontrolled access to δ-lactone-fused-γ-lactams bearing angular benzylic quaternary stereocenters.RSC advances · 2022Article
- Structure-Based Discovery of Lipoteichoic Acid Synthase Inhibitors.Journal of chemical information and modeling · 2022Article
- Dicarboxylic Acid Monoesters in β- and δ-Lactam Synthesis.Molecules (Basel, Switzerland) · 2022Article
- QM/MM modeling of class A β-lactamases reveals distinct acylation pathways for ampicillin and cefalexin.Organic & biomolecular chemistry · 2021Article
- Engineering Cupriavidus necator H16 for the autotrophic production of (R)-1,3-butanediol.Metabolic engineering · 2021Article
- Mechanism of the Kinugasa Reaction Revisited.The Journal of organic chemistry · 2021Article
- TCA Cycle and Its Relationship with Clavulanic Acid Production: A Further Interpretation by Using a Reduced Genome-Scale Metabolic Model ofBioengineering (Basel, Switzerland) · 2021Article
- Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design.Chemical reviews · 2021Review
- Brief survey on organometalated antibacterial drugs and metal-based materials with antibacterial activity.RSC chemical biology · 2021Review
- Development ofFrontiers in bioengineering and biotechnology · 2021Article
- Analysis of β-lactone formation by clinically observed carbapenemases informs on a novel antibiotic resistance mechanism.The Journal of biological chemistry · 2020Article
- Diastereoselective Synthesis of β-Lactams by Ligand-Controlled Stereodivergent Intramolecular Tsuji-Trost Allylation.The Journal of organic chemistry · 2020Article
- Highly enantioselective synthesis of (R)-1,3-butanediol via deracemization of the corresponding racemate by a whole-cell stereoinverting cascade system.Microbial cell factories · 2020Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the 80 years since their discovery the β-lactam antibiotics have progressed through structural generations, each in response to the progressive evolution of bacterial resistance mechanisms. The generational progression was driven by the ingenious, but largely empirical, manipulation of structure by medicinal chemists. Nonetheless, the true creative force in these efforts was Nature, and as the discovery of new β-lactams from Nature has atrophied while at the same time multi-resistant and opportunistic bacterial pathogens have burgeoned, the time for empirical drug discovery has passed. We concisely summarize recent developments with respect to bacterial resistance, the identity of the new β-lactams, and the emerging non-empirical strategies that will ensure that this incredible class of antibiotics has a future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.